Drug: Relistor (methylnaltrexone)

Manufacturer: Salix Pharmaceuticals

Route of Administration: Oral, Subcutaneous

Site of Care: Outpatient

Approved Indication:

• [tablets and injection] treatment of opioid-induced constipation in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation
• [injection] treatment of opioid-induced constipation in adult with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care

Disease: opioid-induced constipation (OIC)

Therapeutic Area: Gastroenterology

Enrollment Form Link: N/A

Phone Number: N/A

Fax Number: N/A

Product Website: relistor.com